UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Earliest event reported) April 12, 2006
BIOPHAN TECHNOLOGIES, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Nevada 0-26057 82-0507874
---------------------------- ------------ -------------------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) file number) Identification No.)
150 Lucius Gordon Drive, Suite 215
West Henrietta, New York 14586
---------------------------------------- ----------
(Address of principal executive offices) (Zip code)
(585) 214-2441
---------------------------------------------------
(Registrant's telephone number including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers
On April 12, 2006, our Vice President for Business Development, John F.
Lanzafame, was appointed Chief Operating Officer. In that position, Mr.
Lanzafame will oversee our sales, marketing and research operations and those of
our subsidiary, Biophan Europe. He will continue to have responsibility for
business development and technology licensing.
In connection with his appointment as Chief Operating Officer, Mr.
Lanzafame has resigned as President of our subsidiary, Nanolution, Inc. Dr.
Stephen H. Curry will assume the role of President of Nanolution, our drug
delivery division. Dr. Curry is a Fellow of the Royal Pharmaceutical Society of
Great Britain and is the author or co-author of over 150 scientific publications
and/or books in the general area of pharmaceuticals, pharmacokinetics and
clinical pharmacology. Before joining Biophan, Dr. Curry held a senior research
and development position with AstraZeneca and was Adjunct Professor of
Pharmacology and Physiology at the University of Rochester.
Item 7.01. Regulation FD Disclosure
On April 12, 2006, we issued a press release announcing the appointment of
Mr. Lanzafame as Chief Operating Officer and of Dr. Curry as President of
Nanolution. A copy of the press release is filed herewith as Exhibit 99.1 and is
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits
Number Exhibit
------ -------
99.1 Press release dated April 12, 2006 entitled "Biophan Appoints
Stephen H. Curry, Ph.D. President of Biophan's Nanolution
Division; John F. Lanzafame Named Biophan Chief Operating
Officer"
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOPHAN TECHNOLOGIES, INC.
Date: April 12, 2006 /s/ Darryl Canfield
-----------------------------------
Darryl Canfield
Chief Financial Officer